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(*) indicates primary project advisor 
Keloids are highly prevalent in the population and their pathogenesis is largely unknown. T-cell 
lymphoma research shows that toll like receptor-4 (TLR-4) is highly expressed on CD206+ 
immunosuppressive macrophages and is implicated in maintaining the tumor microenvironment. 
Additionally, fibronectin, specifically extra domain A (EDA), is highly expressed and is associated 
with immunosuppression via the TLR-4 pathway. Assuming that keloids mimic the tumor 
microenvironment, we hypothesize that TLR-4 is implicated in the pathogenesis of keloids. Using 
keloid tissue samples and normal breast tissue as a control, immunohistochemistry was performed 
to observe the presence and co-localization of these markers. Three antibodies were used to 
examine co-localization of CD-206 with TLR-4 and CD-206 with EDA to determine if these three 
components were localized to the same region in the keloid tissue. The secondary antibodies were 
immunofluorescent, and the tissue was analyzed using electron microscopy. Upon analysis, it was 
found that in keloid tissue CD-206 and TLR-4 were co-localized. To further support the 
hypothesis, it was found that CD-206 and EDA were also co-localized. In the control group, there 
was no evidence of co-localization of CD-206 with TLR-4 or with EDA. These findings support 
the overall hypothesis that TLR-4 is involved in the pathogenesis of keloids. Discovering that CD-
206 co-localizes with both TLR-4 and EDA indicates that these three molecules interact to help 
form the tumor microenvironment needed to support keloid formation. Knowing this information, 
studies can begin to look into possible immunological targets for keloid treatment that access this 
immunosuppressive pathway.  
